American Society of Hematology, Blood, 16(126), p. 1921-1924, 2015
DOI: 10.1182/blood-2015-05-647925
Full text: Download
Key Points CLL patients harboring mutated IGHV genes but neither 11q or 17p deletion experience durable remission after frontline FCR.